Home > Press > American Biotech Labs(R) Obtains FDA Approval for New Wound Care Gel Product
Abstract:
Company's innovative new ASAP Wound Dressing Gel is now approved "for the topical management of minor cuts, lacerations, abrasions, 1st and 2nd degree burns, and skin irritations"
American Biotech Labs, LLC (ABL), developer of a new class of products based on the company's patented nano-catalytic SilverSol Technology(R), today announced that the company has been granted formal approval by the U.S. Food and Drug Administration (FDA) to market its ASAP Wound Dressing Gel throughout the United States.
The FDA approval letter confirms that ABL may market ASAP Wound Dressing Gel "for the topical management of minor cuts, lacerations, abrasions, 1st and 2nd degree burns, and skin irritations." The product utilizes ABL's innovative SilverSol Technology, which has garnered multiple patents in the U.S. and several countries throughout the world, including a broad-use patent that provides the company with exclusive rights to use its silver-based products to combat many of the world's most destructive pathogens, including malaria, tuberculosis, MRSA and HIV.
"We are delighted with the FDA's decision to grant approval for ABL to broadly market our ASAP Wound Dressing Gel," said Dr. William Moeller, a managing director of American Biotech Labs. "We feel this is a singularly effective wound care product, and it is a tremendous validation for us that ABL products have now received approval from the FDA as well as from the EPA."
ABL has performed extensive anti-microbial studies against bacteria, yeast, fungus and other pathogens. Information about these studies is available at research section of the ABL Website, www.americanbiotechlabs.com/researchprotected/researchmenu.html.
####
About American Biotech Labs, LLC
American Biotech Labs (ABL; www.americanbiotechlabs.com), founded in 1998, utilizes patented processes and SilverSol Technology(R) to create singularly powerful and effective nano-catalytic silver products. In extensive testing performed by a variety of respected laboratories and researchers, ABL's silver hydrosol has consistently demonstrated the ability, without any known toxic side effects, to destroy a wide range of bacteria, viruses, yeast, and molds. ABL products have been approved by the by the Environmental Protection Agency (EPA) as a disinfectant for dental water lines, and as a surface disinfectant for bacteria, yeast and mold in hospital, residential, commercial and industrial settings; and by the U.S. Food and Drug Administration (FDA) for wound care. The company's products have been the subject of multiple peer-reviewed articles in professional journals, and are sold worldwide at health food stores and by medical professionals under the Silver Biotics(R) and ASAP Solution(R) brands, and through a variety of private labels.
For more information, please click here
Contacts:
Kimball Thomson
Next Phase Communications
(for American Biotech Labs)
801.918.3637
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||